The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...

SAN FRANCISCO, December 09, 2024--(BUSINESS WIRE)--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...

Organ transplants take a physical, emotional and mental toll. So CSL Behring and Lyfebulb created the first online community for transplant patients, family and friends, and living organ donors.

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post ...

The therapy was approved to treat a rare condition that afflicts about 40,000 people in the United States. The Food and Drug Administration has approved King of Prussia-based CSL Behring’s autoimmune ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. At BIO 2019, happening June 3 to 6 at the Convention Center ...

Moscow opening reinforces CSL Behring's promise to deliver its world-class therapies to patients with rare and serious diseases around the world. KING OF PRUSSIA, Pa. — 08 December 2015 - Global ...

The FDA has accepted CSL Behring’s priority review application for a hemophilia B gene therapy, potentially fast-tracking the drug after a bumpy ride that included a clinical hold—and later, a lift.

A Dutch biotech company developing a gene therapy for hemophilia has made a deal with the U.S.-based division of an Australian company that will enabled it to be marketed around the world.

Recombinant proteins are an innovative class of drugs in which DNA have been reprogrammed or recombined to treat diseases. CSL Behring has long been successful in innovating these technologies, and ...